Company News
- Cyclo Therapeutics Announces Completion of Enrollment in its Extension Protocol to the Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Feb 26, 2020, 8:00 AM EST - Cyclo Therapeutics Announces Completion of Enrollment in its Phase I/II Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Feb 20, 2020, 8:00 AM EST - Last Patient Last Visit in Cyclo Therapeutics’ Phase I Trial in Niemann-Pick Type C
Feb 11, 2020, 8:13 AM EST - Cyclo Therapeutics, Inc. Poster Presentation of Clinical Trial Data on Niemann-Pick Type C Disease at the 16th Annual WORLDSymposium Now Available
Feb 5, 2020, 8:00 AM EST - Cyclo Therapeutics to Present at BIOTECH SHOWCASE™ 2020 in San Francisco
Jan 7, 2020, 8:00 AM EST - Cyclo Therapeutics Signs Master Services Agreement with Worldwide Clinical Trials
Dec 27, 2019, 8:00 AM EST - Cyclo Therapeutics Receives Buy Recommendation and $1.25 Price Target from ThinkEquity
Dec 18, 2019, 7:00 AM EST - Cyclo Therapeutics, Inc. to Present Clinical Trial Data on Niemann-Pick type C Disease at the 16th Annual WORLDSymposium
Dec 16, 2019, 8:00 AM EST - Cyclo Therapeutics’ Chief Scientific Officer Appointed to President’s Council of Advisors on Science and Technology
Dec 10, 2019, 5:10 AM EST - Cyclo Therapeutics Signs Agreement with Worldwide Clinical Trials to Conduct Pivotal Trial in Niemann-Pick Disease Type C
Nov 8, 2019, 8:00 AM EST
